AAP
BPMC

Arax Advisory Partners’s Blueprint Medicines BPMC Stock Holding History

Arax Advisory Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-61
Closed -$7.82K – 3679
2025
Q2 		$7.82K Sell
61
-56
-48% -$5.82K ﹤0.01% 2078
2025
Q1 		$10.4K Buy
117
+67
+134% +$6.54K ﹤0.01% 1557
2024
Q4 		$4.36K Sell
50
-7
-12% -$641 ﹤0.01% 1786
2024
Q3 		$5.27K Sell
57
-5
-8% -$497 ﹤0.01% 1698
2024
Q2 		$6.68K Buy
62
+56
+933% +$5.61K ﹤0.01% 1458
2024
Q1 		$570 Hold
6
– – ﹤0.01% 1226
2023
Q4 		$554 Buy
+6
New +$389 ﹤0.01% 1215
2023
Q2 		– Sell
-7
Closed -$315 – 1276
2023
Q1 		$315 Hold
7
– – ﹤0.01% 1226
2022
Q4 		$307 Buy
+7
New +$336 ﹤0.01% 1215
2022
Q1 		– Sell
-7
Closed -$1K – 1155
2021
Q4 		$1K Hold
7
– – ﹤0.01% 974
2021
Q3 		$1K Buy
+7
New +$652 ﹤0.01% 880

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Arax Advisory Partners's BPMC Position: Q3 2025 in Review

Arax Advisory Partners sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 61 shares — an estimated $7.82K sold.

Arax Advisory Partners first reported a position in BPMC in Q3 2021 and held it in 11 quarters. The position peaked at $10.4K in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Arax Advisory Partners reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 61 Blueprint Medicines shares in Q3 2025, an estimated $7.82K.
  • Arax Advisory Partners first reported a position in Blueprint Medicines in Q3 2021 and held it in 11 quarters.
  • Arax Advisory Partners's Blueprint Medicines position peaked at $10.4K in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Arax Advisory Partners's 13F filing for Q3 2025, filed 14 Nov 2025.